Description: Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in New York, New York.
Home Page: www.mindmed.co
One World Trade Center
New York,
NY
10007
United States
Phone:
212 220 6633
Officers
| Name | Title |
|---|---|
| Mr. Robert Barrow | CEO & Director |
| Dr. Miriam Halperin Wernli Ph.D. | Exec. Pres |
| Dr. Daniel Rollings Karlin M.A., M.D. | Chief Medical Officer |
| Dr. Scott M. Freeman M.D. | Co-Founder & Clinical Advisor |
| Mr. Leonard Latchman | Co-founder |
| Mr. Schond L. Greenway | Chief Financial Officer |
| Ms. Carrie F. Liao CPA, CGMA | VP, Corp. Controller & Accounting Principal |
| Ms. Wong Hu J.D. | Chief Legal Officer & Corp. Sec. |
| Dr. Francois P. Lilienthal M.B.A., M.D. | Chief Commercial Officer |
Exchange: NEO
Country: CA : Canada
Currency: Canadian Dollar (C$)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.6458 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 41 |